BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17979569)

  • 1. Imaging of the distribution of (90)y-ibritumomab tiuxetan in bone marrow and comparison with pathology.
    Coulot J; Camara-Clayette V; Ricard M; Lavielle F; Velasco V; Drusch F; Bosq J; Schlumberger M; Ribrag V
    Cancer Biother Radiopharm; 2007 Oct; 22(5):665-71. PubMed ID: 17979569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.
    Jacobs SA; Harrison AM; Swerdlow SH; Foon KA; Avril N; Vidnovic N; Joyce J; DeMonaco N; McCarty KS
    Mol Imaging Biol; 2009; 11(1):39-45. PubMed ID: 18773247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
    Conti PS; White C; Pieslor P; Molina A; Aussie J; Foster P
    J Nucl Med; 2005 Nov; 46(11):1812-8. PubMed ID: 16269594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
    Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
    Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
    Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
    Chiesa C; Botta F; Coliva A; Maccauro M; Devizzi L; Guidetti A; Carlo-Stella C; Seregni E; Gianni MA; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1745-57. PubMed ID: 19455328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Spies SM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):10-3. PubMed ID: 14762739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
    Arrichiello C; Aloj L; Mormile M; D'Ambrosio L; Frigeri F; Caracò C; Arcamone M; De Martinis F; Pinto A; Lastoria S
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):956-66. PubMed ID: 22237846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
    J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.
    Silverman DH; Delpassand ES; Torabi F; Goy A; McLaughlin P; Murray JL
    Cancer Treat Rev; 2004 Apr; 30(2):165-72. PubMed ID: 15023434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Logistics of therapy with the ibritumomab tiuxetan regimen.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.